Beyond the Fever: Thyrocare Study Shows Nearly 1 in 3 Indian Fever Patients Test Positive for Serious Infections
Mumbai, Mar 27: Thyrocare Technologies Limited (hereinafter referred to as “Thyrocare” NSE: THYROCARE, BSE: 539871), a leading healthcare diagnostics company, has released new insights on India’s fever burden based on testing data collected between 2023 and 2025. The analysis covers over one lakh (108,324) individuals who underwent comprehensive Fever Package testing across PAN India. The findings show that nearly one in three individuals who opted for comprehensive fever testing were diagnosed with a serious infection, including dengue, typhoid, malaria, chikungunya, or leptospirosis.
In India, fever is often brushed off casually. “Just viral.” “Wait it out.” “Rest and basic medication.” But diagnostic data from 2023 to 2025 tells a far more alarming story, one that turns casual reassurance into a dangerous oversight. Behind what appears to be an ordinary fever, a significant proportion of patients were diagnosed with infections that required medical intervention, from dengue and malaria to typhoid and other illnesses. The numbers challenge a deeply rooted cultural habit – to self-diagnose, self-medicate, and wait.
Serious infections detected in a significant share of patients
Typhoid emerged as the most commonly detected infection, identified in nearly one in five patients (18.1%), followed by dengue in about one in seven (14.4%). Malaria, chikungunya and leptospirosis were also recorded across the testing population, further contributing to the overall infectious disease burden.
These findings indicate that a substantial proportion of fever cases are not vague or self-limiting but have clearly identifiable infectious causes. Structured diagnostic testing helps convert clinical uncertainty into timely and targeted medical action.
The data also highlights the presence of multiple infections in a notable proportion of patients. Nearly 10% of infection-positive individuals were diagnosed with co-infections, most commonly a combination of dengue and typhoid. Because these illnesses can present with similar early symptoms but require different treatment approaches, co-infections can complicate diagnosis and delay appropriate care if not identified early.
Rahul Guha, MD & CEO of Thyrocare, said, “Recognising fever as a critical signal empowers patients and clinicians alike to act decisively. It shifts care from reactive treatment to timely and informed intervention. Ultimately, early evaluation, supported by data-driven insights, remains one of the most effective ways to navigate India’s evolving and unpredictable infectious disease landscape.”
Dr Preet Kaur, Chief Scientific Officer, Thyrocare, said, “Data from 2023 to 2025 shows that a significant number of patients carry serious infections, sometimes more than one at a time, revealing patterns that simple assumptions cannot capture. Beyond the visible rise in temperature, laboratory markers highlight hidden stress on organs, from drops in platelet counts to elevated liver enzymes, underscoring that fever is a systemic signal, not an isolated event.”
Infection patterns shifting over time and across regions
The study tracks changes in infection trends between 2023 and 2025. Dengue positivity declined significantly over the three-year period, while malaria increased despite its lower overall base. Typhoid and chikungunya rose in 2024 before easing in 2025 but remained present across the testing population.
Geographic variation was also observed, with transmission levels differing across regions and some areas consistently reporting higher positivity rates than others. At the same time, most regions showed a gradual decline in dengue and typhoid transmission over the three-year period, indicating an overall reduction in transmission levels in several parts of the country.
Fever often signals deeper physiological stress
Laboratory findings show that fever is frequently associated with measurable systemic impact, affecting key physiological markers such as platelet counts and liver function.
Low platelet levels (thrombocytopenia) were observed in 27% of fever patients, nearly double the 15% seen in non-fever cases. The difference was particularly pronounced in malaria-positive patients, where nearly 8 in 10 experienced a platelet drop, compared to a very small proportion among malaria-negative individuals. Dengue-positive patients also showed significant platelet reductions, with 37% affected compared to 15% in dengue-negative cases.
Liver enzyme abnormalities were also widely observed. More than half of all fever patients (56%) showed elevated SGOT levels and 37% had elevated SGPT, both higher than levels seen among non-fever individuals (42% and 26%, respectively). Infection-specific comparisons showed marked liver stress across multiple diseases, including dengue, malaria and leptospirosis.
These findings indicate that infectious fevers are often associated with measurable organ stress, highlighting that fever can reflect broader physiological involvement beyond the presence of infection alone.
The Gender and Seasonal Divide
Gender-based differences were observed across infections. Overall fever positivity was slightly higher among females (32% compared to 29%), largely driven by higher typhoid detection (21% vs 15%). In contrast, malaria affected men more than twice as often as women (1.1% vs 0.5%).
Seasonal patterns were also clearly visible across infections. Dengue positivity rises through the year and typically peaks around October.
Typhoid positivity has steadily fallen from 2023 to its lowest in 2025. Despite a mild monsoon spike each year, 2025 remains consistently lower overall.
Chikungunya positivity rose gradually from lower, volatile levels in 2023, peaked sharply in 2024, and moderated to a softer trend in 2025.
Malaria positivity remains relatively low overall but increases during the monsoon months, with transmission peaking between May and September. Over the three-year period, malaria positivity rose from 0.5% to 1.1%, indicating a gradual increase despite its lower overall base.
Standalone testing also reveals substantial disease burden
Analysis of standalone fever testing across 2.59 lakh patients between 2023 and 2025 recorded an overall positivity rate of 22.6%, indicating a significant infectious disease burden among individuals tested for specific conditions.
Dengue accounted for the highest testing volume, with 1.44 lakh tests conducted and a positivity rate of 16.6%. Typhoid followed with 1.15 lakh tests and a higher positivity rate of 22.7%. Malaria detection remained relatively low at 1.6% despite more than 90,000 tests conducted, while chikungunya, though tested in fewer individuals (27.9K), showed a high positivity rate of 23%.
These findings show that targeted testing for individual infections can detect substantial disease presence. However, standalone testing may not capture overlapping or co-existing infections, highlighting the value of comprehensive diagnostic panels in providing a more complete clinical understanding of fever.
